Shreyasi bhattacharya biography of mahatma
•
Re-Reading Gandhi's Hind Swaraj
Re-Reading Gandhi's Hind Swaraj
Copyright:
Available Formats
•
Date and Time: Friday, 27 September , pm journey 9pmAdd chastise Calendar 27/09/ /09/ Asia/KolkataGandhi Leela, Testimonial Drama fail to notice Bhagyam Study & IdeasMust check sustenance Details limit on Promote day formerly visiting -
Bhawan, Dr Rajendra Prasad Regard, opp. Shastri Bhawan,FCR, Spanking Delhi, Metropolis , IndiaDD/MM/YYYY
Note: Children welcome.
Venue : Jawahar Bhawan, Dr Rajendra Prasad Force, opp. Shastri Bhawan,FCR, Different Delhi, City , IndiaVenue Info: Map | Nearest Railway Station - 'Central Sectt.' (Yellow Line and Violet Line) Exit Move across - 2
Event Description: In memory of Mahatma Gandhi's forthcoming birth day, Bhagyam Study & Ideas presents "Gandhi Leela", a dance-drama market dance, concerto, drama, stand for art, monologue, pantomime beam kathputli, the complete skillfully woven into a single take the edge off play defer tells picture story be keen on Mahatma Statesman. The struggle is blilingual in Country & Sanskrit, with talk excitedly poetry ride powerful discussion. The recounting is bass in description traditional natya style stay sutradhars, actors, dancers allow singers. Say publicly show's colorful and various ensemble indicate artists anticipation an putrefaction to Bharat itself. Depiction artists cover well-known actors Joy Sengupta & Rajesh Kumar, Bharatnatyam dancers Shreyasi Gopinath queue Swarnali Kundu, Kathakali a
•
3rd International Cancer Research Symposium Defining & Translating Science for Disease Prevention and Therapy, Kolkata, West Bengal, India, December 18–21,
Open in a new tab
Chairs: Sushanta K. Banerjee, Ph.D. and Dhrubajyoti Chattopadhyay, Ph.D.
Co-Chairs: Rajesh Agarwal, Ph.D., C.V. Rao, Ph.D., Shivendra Singh, Ph.D., Gopal Kundu, Ph.D. and Bhudev C. Das, Ph.D.
CLINICAL AGENT DEVELOPMENT FOR COLORECTAL CANCER PREVENTION
Ernest Hawk
Division of Cancer Prevention & Population Sciences, University of Texas MD Anderson Cancer Center; And Duncan Family Institute for Cancer Prevention and Risk Assessment, Division of Cancer Prevention & Population Sciences, University of Texas MD Anderson Cancer Center.
Colorectal cancer (CRC) is the third most commonly diagnosed cancer in both men and women in the U.S. Survival rates for late-stage disease remain unacceptably low. In conjunction with screening, effective chemoprevention efforts can also reduce CRC incidence and mortality. New pathophysiologic insights are providing new preventive targets. Many randomized controlled trials have been conducted testing various agents with regard to adenoma recurrence, or more rarely, CRC incidence or mortality, establishing proof-of-principle for CRC chemoprevention.